Home › Research › Treatments
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
Chew EY, Clemons TE, Agrón E, Launer LJ, Grodstein F, Bernstein PS, Age-Related Eye Disease Study 2 (AREDS2) Research Group.. JAMA, 2015-08-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Importance Observational data have suggested that high dietary intake of saturated fat and low intake of vegetables may be associated with increased risk of Alzheimer disease. The composite score provided an overall score for the battery, ranging from -22 to 17, with higher scores representing better function. Results A total of 89% (3741/4203) of AREDS2 participants consented to the ancillary cognitive function study and 93.6% (3501/3741) underwent cognitive function testing. There were no statistically significant differences in change of scores for participants randomized to receive supplements vs those who were not. Analyses were also conducted to assess for potential interactions between LCPUFAs and lutein/zeaxanthin and none were found to be significant. Conclusions and relevance Among older persons with AMD, oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on cognitive function.
What this study adds
Evidence grade: High
This is a trial of 89 participants. In this large randomized trial, supplements of omega-3 fatty acids or lutein/zeaxanthin had no statistically significant effect on cognitive function in older people with age-related macular degeneration. Reported effect size: 93.6%; 57.5%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chew, E. Y., Clemons, T. E., Agrón, E., Launer, L. J., Grodstein, F., & Bernstein, P. S. (2015). Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2015.9677
Vancouver
Chew EY, Clemons TE, Agrón E, Launer LJ, Grodstein F, Bernstein PS. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. JAMA. 2015. doi:10.1001/jama.2015.9677. PMID: 26305649.
BibTeX
@article{chew2015-26305649,
author = {Chew, E. Y. and Clemons, T. E. and Agrón, E. and Launer, L. J. and Grodstein, F. and Bernstein, P. S.},
title = {{Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial}},
journal = {JAMA},
year = {2015},
doi = {10.1001/jama.2015.9677},
pmid = {26305649},
url = {https://doi.org/10.1001/jama.2015.9677}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Importance Observational data have suggested that high dietary intake of saturated fat and low intake of vegetables may be associated with increased risk of Alzheimer disease.
- The composite score provided an overall score for the battery, ranging from -22 to 17, with higher scores representing better function.
- Results A total of 89% (3741/4203) of AREDS2 participants consented to the ancillary cognitive function study and 93.6% (3501/3741) underwent cognitive function testing.
- There were no statistically significant differences in change of scores for participants randomized to receive supplements vs those who were not.
- Analyses were also conducted to assess for potential interactions between LCPUFAs and lutein/zeaxanthin and none were found to be significant.
Why it matters
In this large randomized trial, supplements of omega-3 fatty acids or lutein/zeaxanthin had no statistically significant effect on cognitive function in older people with age-related macular degeneration. This means these supplements did not help prevent cognitive decline in this group.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants89
- Effect size93.6%; 57.5%
- Evidence strengthHigh
How this study scored 73/100
Published in a top-tier journal, and it is a randomized controlled trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 89 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 5 / 7 | Cited 191 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 14.7 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 4 / 6 | Cited 17.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 37 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Paul S. Bernstein: h-index 73 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 26305649) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 73 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “omega-3-supplements-and-cognition”
3 studies in the library carry the topic tag “omega-3-supplements-and-cognition”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.